ZJY-54

ZJY-54: sourced facts only. name: "To address the challenges, we herein reported the structure-based design of new LSD1/EGFR dual inhibitors, of which ZJY-54 represents the shortlisted lead compound with high potency, selectivity, and unique dual modes of action (namely irreversibly binding to EGFR but reversibly binding to LSD1)." [PMID:40015914]; target: "To address the challenges, we herein reported the structure-based design of new LSD1/EGFR dual inhibitors, of which ZJY-54 represents the shortlisted lead compound with high potency, selectivity, and unique dual modes of action (namely irreversibly binding to EGFR but reversibly binding to LSD1)." [PMID:40015914]; developer: "College of Chemistry, Pingyuan Laboratory, Zhengzhou University, Zhengzhou 450001, China." [PMID:40015914]; stage: "ZJY-54 showed favorable PK profiles and effectively inhibited tumor growth in the H1975 xenograft model." [PMID:40015914]